Bicalutamide Placebo

Phase 3

AAragon Pharmaceuticals, Inc.

Bicalutamide Placebo is one of 18 therapeutic programs targeting Prostatic Neoplasms. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Prostatic NeoplasmsActive, not recruiting

Prostatic NeoplasmsPhase 3

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Prostatic Neoplasms

#DrugCompanyPhaseTrials

Erleada

Johnson & Johnson

Approved

9 2

Zytiga

Johnson & Johnson

Phase 3

6 3

Xtandi

Astellas

Phase 3

3 4

Verzenio

Eli Lilly

Phase 3

2 5

Rayos

RRoxane Laboratories

Phase 3

4 6

Androgen Deprivation Therapy

Johnson & Johnson

Phase 3

3 7

Gnrh

MMassachusetts General Hospital

Phase 3

1 8

Pasritamig

Johnson & Johnson

Phase 3

2 9

Prednisone or Prednisolone

Johnson & Johnson

Phase 3

1 10

Lhrha

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Active, not recruiting

Prostatic Neoplasms

NCT02531516

Clinical

Trials by Indication[1]

Prostatic Neoplasms1 trial

ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy

Active, not recruiting·AAragon Pharmaceuticals, Inc.·Phase 3·NCT02531516·1,503 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Bicalutamide Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Bicalutamide Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Aragon Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AAragon Pharmaceuticals, Inc.

Bicalutamide Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Prostatic Neoplasms1 trial

References

Drug Info

Quick Facts

Related News